Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota
Barbara Lomeli(IQVIA (United States)), Nebojša Janjić(Nivalis Therapeutics (United States)), Wael Elamin, Urs A. Ochsner(Crestone (United States)), Blaire L. Osborn(National Institutes of Health), Jacques Ravel(Human Genome Sciences (United States)), Jared Schettler(IQVIA (United States)), Hal Galbraith(IQVIA (United States)), Catherine Lozupone(Colorado School of Public Health), Thale C. Jarvis(Crestone (United States)), Keith Z. Hazleton(Children's Hospital Colorado), Ronald J. Evans(Crestone (United States)), Stacie Bell(Crestone (United States)), Shahida Baqar(Naval Medical Research Command), George A. Saviolakis
Cited by 38
Related Papers
QIIME allows analysis of high-throughput community sequencing data
|Nature Methods|2010|36k
Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample
|Proceedings of the National Academy of Sciences|2010|10.1k
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
|Applied and Environmental Microbiology|2005|8.6k
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k